{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-26-000044","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.294557+00:00","generated_at":"2026-05-15T00:03:36.633388+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biohaven Q1 net loss $130.5M; pivotal epilepsy & obesity data due 2H 2026","bullets":["Net loss $130.5M ($0.88/sh) vs $221.7M ($2.17/sh) in Q1 2025; non-GAAP adjusted loss $102.2M ($0.69/sh).","Cash, equivalents & securities totaled $351.8M at March 31, 2026.","R&D spend fell to $103.8M from $187.6M, driven by program reprioritization and lower share-based compensation.","Pivotal epilepsy (opakalim) topline readout and Phase 2 obesity (taldefgrobep) data expected in 2H 2026.","Pivotal trials for BHV-1400 (IgAN) and BHV-1300 (Graves' disease) expected to initiate mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-26-000044","json":"https://secwatch.observer/filing/0001935979-26-000044.json","markdown":"https://secwatch.observer/filing/0001935979-26-000044.md","text":"https://secwatch.observer/filing/0001935979-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/0001935979-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/bhvn-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:03:36.633388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc0aea2f855b876ab9beea815160f07d1772c930","claim":"Biohaven Ltd. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 4, 2026, Biohaven Ltd. (the \" Registrant \") issued a press release announcing its financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/0001935979-26-000044-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}